WO2007091151A3 - Composition synergique pharmaceutique et/ou nutraceutique de flavanoides pour le traitement du diabete sucre - Google Patents

Composition synergique pharmaceutique et/ou nutraceutique de flavanoides pour le traitement du diabete sucre Download PDF

Info

Publication number
WO2007091151A3
WO2007091151A3 PCT/IB2007/000290 IB2007000290W WO2007091151A3 WO 2007091151 A3 WO2007091151 A3 WO 2007091151A3 IB 2007000290 W IB2007000290 W IB 2007000290W WO 2007091151 A3 WO2007091151 A3 WO 2007091151A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
flavanoid
neutraceutical
management
diabetes mellitus
Prior art date
Application number
PCT/IB2007/000290
Other languages
English (en)
Other versions
WO2007091151A2 (fr
Inventor
Sunil Bhaskaran
Mohan Vishwaraman
Original Assignee
Indus Biotech Private Ltd
Sunil Bhaskaran
Mohan Vishwaraman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indus Biotech Private Ltd, Sunil Bhaskaran, Mohan Vishwaraman filed Critical Indus Biotech Private Ltd
Publication of WO2007091151A2 publication Critical patent/WO2007091151A2/fr
Publication of WO2007091151A3 publication Critical patent/WO2007091151A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition synergique pharmaceutique et/ou nutraceutique de flavanoïdes pour le traitement du diabète sucré, ladite composition comprenant un polyphénol à une concentration comprise entre 85 et 95 % (poids/poids), de la GAE théobromine à une concentration comprise entre 1 et 5 % (poids/poids) et une humidité comprise entre 0,5 et 10 % (volume/poids).
PCT/IB2007/000290 2006-02-06 2007-02-02 Composition synergique pharmaceutique et/ou nutraceutique de flavanoides pour le traitement du diabete sucre WO2007091151A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN00154/CHE/2006 2006-02-06
IN154CH2006 2006-02-06

Publications (2)

Publication Number Publication Date
WO2007091151A2 WO2007091151A2 (fr) 2007-08-16
WO2007091151A3 true WO2007091151A3 (fr) 2008-04-24

Family

ID=38345515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/000290 WO2007091151A2 (fr) 2006-02-06 2007-02-02 Composition synergique pharmaceutique et/ou nutraceutique de flavanoides pour le traitement du diabete sucre

Country Status (1)

Country Link
WO (1) WO2007091151A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563601B2 (en) * 2010-07-28 2013-10-22 Indus Biotech Private Limited Method of managing broncho-constrictive condition
WO2014090512A1 (fr) 2012-12-13 2014-06-19 Unilever N.V. Composition comestible
TWI736754B (zh) * 2017-04-03 2021-08-21 大江生醫股份有限公司 含有植物萃取物之組成物其於促進膠原蛋白增生之用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093690A2 (fr) * 2000-06-09 2001-12-13 Mars, Incorporated Procede ameliore d'extraction de procyanidines de cacao
WO2002014251A1 (fr) * 2000-08-11 2002-02-21 Barry Callebaut Ag. Procede d'obtention d'extraits polyphenoliques de feves de cacao, les extraits obtenus et leurs applications
FR2873895A1 (fr) * 2004-08-06 2006-02-10 Elysee Lab Procede d'obtention d'un cacao permettant de fabriquer un chocolat essentiellement exempt de sucre et d'edulcorants ainsi que produits issus de la mise en oeuvre de ce procede

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093690A2 (fr) * 2000-06-09 2001-12-13 Mars, Incorporated Procede ameliore d'extraction de procyanidines de cacao
WO2002014251A1 (fr) * 2000-08-11 2002-02-21 Barry Callebaut Ag. Procede d'obtention d'extraits polyphenoliques de feves de cacao, les extraits obtenus et leurs applications
FR2873895A1 (fr) * 2004-08-06 2006-02-10 Elysee Lab Procede d'obtention d'un cacao permettant de fabriquer un chocolat essentiellement exempt de sucre et d'edulcorants ainsi que produits issus de la mise en oeuvre de ce procede

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALZER J ET AL: "Improvement of endothelial function in diabetic subjects after consumption of flavanol-rich cocoa", EUROPEAN HEART JOURNAL, THE EUROPEAN SOCIETY OF CARDIOLOGY, XX, vol. 27, no. Suppl 1, August 2006 (2006-08-01), pages 112, XP009094740, ISSN: 0195-668X *
GRASSI DAVIDE ET AL: "Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 81, no. 3, March 2005 (2005-03-01), pages 611 - 614, XP002465994, ISSN: 0002-9165 *
RUZAIDI A ET AL: "The effect of Malaysian cocoa extract on glucose levels and lipid profiles in diabetic rats", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 98, no. 1-2, 8 April 2005 (2005-04-08), pages 55 - 60, XP004780626, ISSN: 0378-8741 *
WOLLGAST JAN ET AL: "Review on polyphenols in Theobroma cacao: Changes in composition during the manufacture of chocolate and methodology for identification and quantification", FOOD RESEARCH INTERNATIONAL, vol. 33, no. 6, 2000, pages 423 - 447, XP002465993, ISSN: 0963-9969 *

Also Published As

Publication number Publication date
WO2007091151A2 (fr) 2007-08-16

Similar Documents

Publication Publication Date Title
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2007109192A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2008048963A3 (fr) Compositions naturelles pour tuer des parasites sur un animal de compagnie
WO2007045252A3 (fr) Composition comestible
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
IL195030A (en) IV dpp inhibitor assemblies
WO2007030409A3 (fr) Compositions antimicrobiennes de revetement a sec et en bidon possedant des analogues hydroxy de methionine et de derives associes
WO2006096434A3 (fr) Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
MY160703A (en) Crystalline forms of (r) -5- [3-chloro-4-(2,3-dihydroxy) - benz [z] ylidene] -2- ([z]-propylimino) -3-0-tolyl-thiazolidin-4-one
WO2007139955A3 (fr) Composés de triazole qui modulent l'activité de la hsp90
WO2007139967A3 (fr) Composés de triazole modulant l'activité de hsp90
WO2007139968A3 (fr) Composés de triazole qui modulent l'activité de la hsp90
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
WO2008047061A3 (fr) Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine eventuellement associee a au moins un compose polyphenol et composition correspondante
WO2008006528A3 (fr) Nouvelles compositions pharmaceutiques comprenant du lévétiracétam
WO2007084221A9 (fr) Procédés et appareil pour l'identification de matière dans des données de visualisation
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007027651A3 (fr) Compositions pharmaceutiques utilisees comme inhibiteurs de la dipeptidyl peptidase iv (dpp-iv)
WO2008017346A3 (fr) Utilisation de dérivés d'acide ascorbique pour la fonctionnalisation de matrices
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
WO2005086656A3 (fr) Derives d'heteroarylaminopyrazole utilises pour traiter le diabete
WO2008070268A3 (fr) Compositions pharmaceutiques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07700539

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07700539

Country of ref document: EP

Kind code of ref document: A2